Surfactant Nebulization for the Early Aeration of the Preterm Lung
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Respiratory distress syndrome is the most common cause of respiratory failure in preterm
infants. Treatment consists of respiratory support and exogenous surfactant administration.
Commonly, surfactant is administered via an endotracheal tube during mechanical ventilation.
However, mechanical ventilation is considered an important risk factor for developing
bronchopulmonary dysplasia.
Surfactant nebulisation during noninvasive ventilation may offer an alternative method for
surfactant administration and has been shown to be promising in terms of physiological as
well as clinical changes. In preterm infants with respiratory distress syndrome, the effect
of intratracheally administered surfactant on lung function during invasive ventilation has
been studied extensively. However, the effect of early postnatal surfactant nebulization
remains unclear.
Therefore, the investigators plan to conduct a randomized controlled trial in order to
investigate the effect of surfactant nebulization immediately after birth on early postnatal
lung volume and short-term respiratory stability.